Pelthos Therapeutics Announces CFO Transition
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: GlobeNewswire
DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos’ Chief Financial Officer since July 2025. “John played a key role in helping us establish and launch Pelthos. He is an experienced financial leader, and we are excited to have him step into this new role as we continue our strong commercial momentum and enter the next phase of the company's growth,” said Scott Plesha, CEO of Pelthos. “We also want to thank Frank for his dedication and contributions following our merger with Channel Therapeutics Corporation and during our two recent significant capital raises.” Mr. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has mo
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumGlobeNewswire
- Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye PainGlobeNewswire
- Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... [Yahoo! Finance]Yahoo! Finance
PTHS
Earnings
- 3/19/26 - Miss
PTHS
Sec Filings
- 4/14/26 - Form 8-K
- 4/10/26 - Form 8-K
- 4/6/26 - Form 4
- PTHS's page on the SEC website